Search

Your search keyword '"Nieuwkerk, Pythia T"' showing total 439 results
Start Over Author "Nieuwkerk, Pythia T"
439 results on '"Nieuwkerk, Pythia T"'

2. Effect of a customized digital adherence tool on retention in care and adherence to antiretroviral treatment in breastfeeding women, children and adolescents living with HIV in Tanzania: a mixed-methods study followed by clinical trials

Author

Sumari-de Boer, I. Marion, Ngowi, Kennedy M., Swai, Iraseni U., Masika, Lyidia V., Maro, Rehema A., Mtenga, Alan E., Mtesha, Benson A., Nieuwkerk, Pythia T., Reis, Ria, de Wit, Tobias F. Rinke, and Aarnoutse, Rob E.

Published
2023
Full Text
View/download PDF

5. Adherence to preventive measures after SARS-CoV-2 vaccination and after awareness of antibody response in kidney transplant recipients in the Netherlands: a nationwide questionnaire study

Author

Imhof, C., Idzinga, C., Siegert, C., Baan, C.C., Konings, C.J.A.M., van Kessel, C., van Baarle, D., Diavatopoulos, D.A., Standaar, D., ten Hoope, E., Til, E., Remmerswaal, E.B.M., van der Klis, F., Fritsen, H.R., Stijnman, I., Brinkman, J.N., Cheng, J., den Biggelaar, L., ten Dam, M., Steenhuis, M., Zwerink, M., Braks, M.H.J., Willems, M., Kho, M.L., Rots, N., Vart, P., van der Molen, R.G., van den Dorpel, R.M.A., Malaha, R.S.R.K., ter Meulen, R.C.G., Rispens, T., Steenvoorden, T., de Ronde, T., Peters, V.J.P., Konijn, W.S., Janssen, W.M.T., Bos, W.J., Adema, Y.M.R., Vegting, Y., Frölke, Sophie C., Bouwmans, Pim, Messchendorp, A. Lianne, Vervoort, Johanna P.M., Abrahams, Alferso C., de Vries, Aiko P.J., Nieuwkerk, Pythia T., Hemmelder, Marc H., Gansevoort, Ron T., Hilbrands, Luuk B., Reinders, Marlies E.J., Sanders, Jan-Stephan F., Bemelman, Frederike J., and Geerlings, Suzanne E.

Published
2023
Full Text
View/download PDF

8. Response shift after coronary revascularization

Author

Oreel, Tom H., Nieuwkerk, Pythia T., Hartog, Iris D., Netjes, Justine E., Vonk, Alexander B. A., Lemkes, Jorrit, van Laarhoven, Hanneke W. M., Scherer-Rath, Michael, Henriques, José P. S., Oort, Frans J., Sprangers, Mirjam A. G., and Verdam, Mathilde G. E.

Published
2022
Full Text
View/download PDF

10. Perceptions of Rapid Antiretroviral Therapy Initiation Among Participants of The Netherlands Cohort Study on Acute HIV Infection

Author

DIGD-Medisch 1, Infection & Immunity, van Paassen, Pien, Dijkstra, Maartje, Peay, Holly L., Rokx, Casper, Verbon, Annelies, Reiss, Peter, Prins, Jan M., Henderson, Gail E., Rennie, Stuart, Nieuwkerk, Pythia T., de Bree, Godelieve J., DIGD-Medisch 1, Infection & Immunity, van Paassen, Pien, Dijkstra, Maartje, Peay, Holly L., Rokx, Casper, Verbon, Annelies, Reiss, Peter, Prins, Jan M., Henderson, Gail E., Rennie, Stuart, Nieuwkerk, Pythia T., and de Bree, Godelieve J.

Published
2024

16. Perceptions of Rapid Antiretroviral Therapy Initiation Among Participants of The Netherlands Cohort Study on Acute HIV Infection.

Author

van Paassen, Pien, Dijkstra, Maartje, Peay, Holly L., Rokx, Casper, Verbon, Annelies, Reiss, Peter, Prins, Jan M., Henderson, Gail E., Rennie, Stuart, Nieuwkerk, Pythia T., and de Bree, Godelieve J.

Abstract

Starting antiretroviral therapy (ART) same-day, or as soon as possible after HIV diagnosis is advised in guidelines worldwide. Especially during acute HIV infection (AHI), rapid ART start may be more urgent because of a higher risk of transmission or symptoms of acute retroviral syndrome. During this phase, rapid ART start may have additional benefits for viral reservoir size and host immunity. We explored perceptions of rapid ART start among participants of The Netherlands Cohort Study on Acute HIV infection (NOVA study), who started ART rapidly after diagnosis of AHI. We conducted 20 in-depth qualitative interviews with NOVA study participants between October and December 2018. Data were analyzed thematically, using inductive and iterative coding techniques. Roughly half of the participants stated they felt well-informed about the importance of (rapid) ART. Starting ART rapidly was perceived positively by almost all participants, mostly because of the expected benefits on their health, and to prevent HIV transmission. Rapid ART start was seen as a way to cope with the diagnosis. However, a more negative perception was that rapid ART start confronted participants with their diagnosis, when they were still adjusting to a new situation. Our results show that among people diagnosed during AHI, rapid ART is well-accepted. These results should be encouraging to HIV care providers who encounter people with AHI in their clinical practice and to researchers who carry out cure-related studies, in which early ART is often included. The Clinical Trial Registration number is NCT05728996. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Optimising HIV care using information obtained from PROMs: protocol for an observational study

Author

Moody, Kevin, primary, Nieuwkerk, Pythia T, additional, Bedert, Maarten, additional, Nellen, Jeannine F, additional, Weijsenfeld, Annouschka, additional, Sigaloff, Kim C E, additional, Laan, Laura, additional, Bruins, Claire, additional, van Oers, Hedy, additional, Haverman, Lotte, additional, Geerlings, Suzanne E, additional, and Van der Valk, Marc, additional

Published
2023
Full Text
View/download PDF

19. Perceptions of Rapid Antiretroviral Therapy Initiation Among Participants of The Netherlands Cohort Study on Acute HIV Infection

Author

van Paassen, Pien, primary, Dijkstra, Maartje, additional, Peay, Holly L., additional, Rokx, Casper, additional, Verbon, Annelies, additional, Reiss, Peter, additional, Prins, Jan M., additional, Henderson, Gail E., additional, Rennie, Stuart, additional, Nieuwkerk, Pythia T., additional, and de Bree, Godelieve J., additional

Published
2023
Full Text
View/download PDF

20. Which symptom to address in psychological treatment for cancer survivors when fear of cancer recurrence, depressive symptoms, and cancer-related fatigue co-occur? Exploring the level of agreement between three systematic approaches to select the focus of treatment

Author

Harnas, Susan J., primary, Booij, Sanne H., additional, Csorba, Irene, additional, Nieuwkerk, Pythia T., additional, Knoop, Hans, additional, and Braamse, Annemarie M. J., additional

Published
2023
Full Text
View/download PDF

21. Adherence to preventive measures after SARS-CoV-2 vaccination and after awareness of antibody response in kidney transplant recipients in the Netherlands: a nationwide questionnaire study

Author

Frölke, Sophie C., primary, Bouwmans, Pim, additional, Messchendorp, A. Lianne, additional, Vervoort, Johanna P.M., additional, Abrahams, Alferso C., additional, de Vries, Aiko P.J., additional, Nieuwkerk, Pythia T., additional, Hemmelder, Marc H., additional, Gansevoort, Ron T., additional, Hilbrands, Luuk B., additional, Reinders, Marlies E.J., additional, Sanders, Jan-Stephan F., additional, Bemelman, Frederike J., additional, Geerlings, Suzanne E., additional, Imhof, C., additional, Idzinga, C., additional, Siegert, C., additional, Baan, C.C., additional, Konings, C.J.A.M., additional, van Kessel, C., additional, van Baarle, D., additional, Diavatopoulos, D.A., additional, Standaar, D., additional, ten Hoope, E., additional, Til, E., additional, Remmerswaal, E.B.M., additional, van der Klis, F., additional, Fritsen, H.R., additional, Stijnman, I., additional, Brinkman, J.N., additional, Cheng, J., additional, den Biggelaar, L., additional, ten Dam, M., additional, Steenhuis, M., additional, Zwerink, M., additional, Braks, M.H.J., additional, Willems, M., additional, Kho, M.L., additional, Rots, N., additional, Vart, P., additional, van der Molen, R.G., additional, van den Dorpel, R.M.A., additional, Malaha, R.S.R.K., additional, ter Meulen, R.C.G., additional, Rispens, T., additional, Steenvoorden, T., additional, de Ronde, T., additional, Peters, V.J.P., additional, Konijn, W.S., additional, Janssen, W.M.T., additional, Bos, W.J., additional, Adema, Y.M.R., additional, and Vegting, Y., additional

Published
2023
Full Text
View/download PDF

25. Adherence to preventive measures after SARS-CoV-2 vaccination and after awareness of antibody response in kidney transplant recipients in the Netherlands:a nationwide questionnaire study

Author

Frölke, Sophie C., Bouwmans, Pim, Messchendorp, A. Lianne, Vervoort, Johanna P.M., Abrahams, Alferso C., de Vries, Aiko P.J., Nieuwkerk, Pythia T., Hemmelder, Marc H., Gansevoort, Ron T., Hilbrands, Luuk B., Reinders, Marlies E.J., Sanders, Jan Stephan F., Bemelman, Frederike J., Geerlings, Suzanne E., van der Molen, R. G., Frölke, Sophie C., Bouwmans, Pim, Messchendorp, A. Lianne, Vervoort, Johanna P.M., Abrahams, Alferso C., de Vries, Aiko P.J., Nieuwkerk, Pythia T., Hemmelder, Marc H., Gansevoort, Ron T., Hilbrands, Luuk B., Reinders, Marlies E.J., Sanders, Jan Stephan F., Bemelman, Frederike J., Geerlings, Suzanne E., and van der Molen, R. G.

Abstract

Background: Kidney transplant recipients (KTRs) were advised to tightly adhere to government recommendations to curb the spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) because of a high risk of morbidity and mortality and decreased immunogenicity after vaccination. The aim of this study was to analyse the change in adherence to preventive measures after vaccination and awareness of antibody response, and to evaluate its effectiveness. Methods: In this large-scale, national questionnaire study, questionnaires were sent to 3531 KTRs enrolled in the Dutch RECOVAC studies, retrospectively asking for adherence to nine preventive measures on a 5-point Likert scale before and after SARS-CoV-2 vaccination and after awareness of antibody response. Blood samples were collected 28 days after the second vaccination. Antibody response was categorised as non-responder (≤50 BAU/mL), low-responder (>50 ≤ 300 BAU/mL) or high-responder (>300 BAU/mL), and shared with participants as a correlate of protection. Participants of whom demographics on sex and age, blood samples and completed questionnaires were available, were included. Our study took place between February 2021 and January 2022. The primary outcome of adherence before and after vaccination was assessed between August and October 2021 and compared via the Wilcoxon signed rank sum test. Logistic regression analysis was performed to estimate the association between antibody response and non-adherence, and adherence on acquiring SARS-CoV-2 infection. This study is registered at ClinicalTrials.gov (NCT04841785). Findings: In 2939 KTRs (83%) who completed the first questionnaire on adherence to preventive measures, adherence was higher before than after vaccination (4.56, IQR 4.11–4.78 and 4.22, IQR 3.67–4.67, p < 0.001). Adherence after awareness of antibody response was analysed in 2399 KTRs (82%) of whom also blood samples were available, containing 949 non-responders, 500 low-responders an

Published
2023

26. Effect of a customized digital adherence tool on retention in care and adherence to antiretroviral treatment in breastfeeding women, children and adolescents living with HIV in Tanzania : a mixed-methods study followed by clinical trials

Author

Sumari-de Boer, I.M., Ngowi, Kennedy M., Swai, Iraseni U., Masika, Lyidia V., Maro, Rehema A., Mtenga, Alan E., Mtesha, Benson A., Nieuwkerk, Pythia T., Reis, Ria, de Wit, Tobias F.R., Aarnoutse, Rob E., Sumari-de Boer, I.M., Ngowi, Kennedy M., Swai, Iraseni U., Masika, Lyidia V., Maro, Rehema A., Mtenga, Alan E., Mtesha, Benson A., Nieuwkerk, Pythia T., Reis, Ria, de Wit, Tobias F.R., and Aarnoutse, Rob E.

Abstract

Background: Adherence to antiretroviral (ARV) treatment for HIV infection is challenging because of many factors. The World Health Organization (WHO) has recommended using digital adherence technologies (DATs). However, there is limited evidence on how DATs improve adherence. Wisepill® is an internet-enabled medication dispenser found feasible and acceptable in several studies. However, limited evidence is available on its effectiveness in improving ART adherence, specifically among children and adolescents. Furthermore, DATs are often developed without involving the target groups. We propose a two-stage project consisting of a formative study to customize an existing Wisepill DAT intervention and a randomized clinical trial to investigate the effectiveness of DAT combined with reminder cues and tailored feedback on adherence to ARV treatment among children and adolescents living with HIV and retention in care among breastfeeding women living with HIV in Kilimanjaro and Arusha Region, Tanzania. Methods: We will conduct a formative mixed-methods study and three sub-trials in Kilimanjaro and Arusha Regions among (1) children aged 0–14 years and their caregivers, (2) adolescents aged 15–19 years and (3) breastfeeding women and their HIV-negative infants. In the formative study, we will collect and analyse data on needs and contents for DATs, including the contents of short message service (SMS) texts and tailored feedback. The results will inform the customization of the DAT to be tested in the sub-trials. In the trials, participants will be randomized in the intervention arm, where the DAT will be implemented or the control arm, where standard care will be followed. Participants in the intervention arm will take their medication from the Wisepill box and receive daily reminder texts and tailored feedback during clinic visits. Discussion: If the intervention improves adherence to ART and the devices are acceptable, accurate and sustainable, the intervention can be scal

Published
2023

27. Patient preferences regarding treatment options for Waldenström's macroglobulinemia: A discrete choice experiment

Author

MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Amaador, Karima, Nieuwkerk, Pythia T, Minnema, Monique C, Kersten, Marie José, Vos, Josephine M I, MS Hematologie, Infection & Immunity, Regenerative Medicine and Stem Cells, Cancer, Amaador, Karima, Nieuwkerk, Pythia T, Minnema, Monique C, Kersten, Marie José, and Vos, Josephine M I

Published
2023

28. Long-term fear of cancer recurrence in patients treated endoscopically for early Barrett's neoplasia

Author

Rosmolen, Wilda D., Pouw, Roos E., van Berge Henegouwen, Mark I., Bergman, Jacques J., Sprangers, Mirjam A., Nieuwkerk, Pythia T., Graduate School, CCA - Cancer Treatment and Quality of Life, CCA - Imaging and biomarkers, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, Gastroenterology and Hepatology, Medical Psychology, APH - Aging & Later Life, APH - Mental Health, AII - Inflammatory diseases, APH - Personalized Medicine, Gastroenterology and hepatology, CCA - Cancer Treatment and quality of life, and Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
Gastroenterology, General Medicine
Abstract

Summary Previous studies on fear of cancer recurrence after endoscopic treatment for early Barrett’s neoplasia focused on fear during a relatively short period after the intervention. The aim of this study was to explore whether fear of cancer (recurrence) persists during long-term follow-up in patients treated endoscopically for Barrett’s neoplasia compared to patients treated surgically for a more advanced stage of esophageal adenocarcinoma. Participants previously participated in a prospective longitudinal study investigating quality of life and fear of cancer recurrence and were treated endoscopically for early Barrett’s neoplasia (high-grade dysplasia—T1sm1N0M0) or surgically for a more advanced esophageal adenocarcinoma (T1N0M0–T3N1M0). For the present study, participants were again invited to complete a set of questionnaires including the fear of cancer recurrence scale (FORS), worry for cancer scale (WOCS), and the anxiety subscale of the Hospital Anxiety and Depression Scale (HADS Anxiety). Thirty-nine patients were eligible in the endoscopy group and 28 in the surgical group. The median time between the baseline measurement (original study) and the long-term follow-up assessment was 4 years (interquartile range 3–5 years). Fear and worry for cancer recurrence and general anxiety diminished over time in both treatment groups. However, at long-term follow-up, endoscopically treated patients had significantly higher levels of worry for cancer and general anxiety than surgically treated patients. Fear of cancer recurrence did not significantly differ between endoscopically and surgically treated patients. We found that worry and fear of cancer recurrence and general anxiety in endoscopically treated patients declined over time, but not as much as in surgically treated patients.

Published
2023
Full Text
View/download PDF

30. Implementation and effectiveness of evriMED with short messages service (SMS) reminders and tailored feedback compared to standard care on adherence to treatment among tuberculosis patients in Kilimanjaro, Tanzania: proposal for a cluster randomized controlled trial

Author

Sumari-de Boer, Marion, Pima, Francis M., Ngowi, Kennedy M., Chelangwa, Geoffrey M., Mtesha, Benson A., Minja, Linda M., Semvua, Hadija H., Mpagama, Stella, Mmbaga, Blandina T., Nieuwkerk, Pythia T., and Aarnoutse, Rob E.

Published
2019
Full Text
View/download PDF

31. One-fourth of COVID-19 patients have an impaired pulmonary function after 12 months of disease onset.

Author

van Willigen, Hugo D. G., Wynberg, Elke, Verveen, Anouk, Dijkstra, Maartje, Verkaik, Bas J., Figaroa, Orlane J. A., de Jong, Marianne C., van der Veen, Annelou L. I. P., Makowska, Agata, Koedoot, Nelleke, Nieuwkerk, Pythia T., Boyd, Anders, Prins, Maria, de Jong, Menno D., de Bree, Godelieve J., and van den Aardweg, Joost G.

Subjects
COVID-19, PULMONARY function tests, QUALITY of life, CARBON monoxide, LOGISTIC regression analysis, PLETHYSMOGRAPHY
Abstract

Background: There is increasing data that show a persistently impaired pulmonary function upon recovery after severe infection. Little is known however about the extent, recovery and determinants of pulmonary impairment across the full spectrum of COVID-19 severity over time. Methods: In a well characterized, prospective cohort of both hospitalised and non-hospitalised individuals with SARS-CoV-2 infection, the RECoVERED study, pulmonary function (diffusing capacity for carbon monoxide (DLCO)) and spirometry) was measured until one year after disease onset. Additionally, data on sociodemographics, clinical characteristics, symptoms, and health-related quality of life (HRQL) were collected. Pulmonary function and these determinants were modelled over time using mixed-effect linear regression. Determinants of pulmonary function impairment at 12 months after disease onset were identified using logistic regression. Findings: Between May 2020 and December 2021, 301 of 349 participants underwent at least one pulmonary function test. After one year of follow-up, 25% of the participants had an impaired pulmonary function which translates in 11%, 22%, and 48% of the participants with mild, moderate and severe/critical COVID-19. Improvement in DLCO among the participants continued over the period across one, six and twelve months. Being older, having more than three comorbidities (p<0·001) and initial severe/critical disease (p<0·001) were associated with slower improvement of pulmonary function over time, adjusted for age and sex. HRQL improved over time and at 12 months was comparable to individuals without impaired pulmonary function. Interpretation: The prevalence of impaired pulmonary function after twelve months of follow-up, was still significant among those with initially moderate or severe/critical COVID-19. Pulmonary function increased over time in most of the severity groups. These data imply that guidelines regarding revalidation after COVID-19 should target individuals with moderate and severe/critical disease severities. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Kidney Transplant Recipients Become Less Adherent to Preventive Measures after SARS‑CoV‑2 Vaccination and after Awareness of Antibody Response

Author

Frölke, Sophie, primary, Bouwmans, Pim, additional, Messchendorp, A. Lianne, additional, Vervoort, Johanna PM, additional, Nieuwkerk, Pythia T., additional, Hemmelder, Marc H., additional, Gansevoort, Ron T., additional, Hilbrands, Luuk B., additional, Reinders, Marlies EJ, additional, Sanders, Jan-Stephan, additional, Bemelman, Frederike J., additional, Geerlings, Suzanne E., additional, and Collaborators, RECOVAC, additional

Published
2023
Full Text
View/download PDF

33. One-Fourth of COVID-19 Patients Have an Impaired Pulmonary Function after 12 Months of Illness Onset

Author

van Willigen, Hugo D.G., primary, Wynberg, Elke, additional, Verveen, Anouk, additional, Dijkstra, Maartje, additional, Verkaik, Bas J., additional, Figaroa, Orlane J.A., additional, de Jong, Marianne C., additional, van Veen, Annelou, additional, Makowska, Agata, additional, Koedoot, Nelleke, additional, Nieuwkerk, Pythia T., additional, Boyd, Anders, additional, Prins, Maria, additional, de Bree, Godelieve J., additional, de Jong, Menno D., additional, and Aardweg, Joost G. van den, additional

Published
2023
Full Text
View/download PDF

44. Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection

Author

van Paassen, Pien, primary, Dijkstra, Maartje, additional, Peay, Holly L., additional, Rokx, Casper, additional, Verbon, Annelies, additional, Reiss, Peter, additional, Prins, Jan M., additional, Henderson, Gail E., additional, Rennie, Stuart, additional, Nieuwkerk, Pythia T., additional, and de Bree, Godelieve J., additional

Published
2022
Full Text
View/download PDF

45. Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection

Author

van Paassen, Pien, Dijkstra, Maartje, Peay, Holly L., Rokx, Casper, Verbon, Annelies, Reiss, Peter, Prins, Jan M., Henderson, Gail E., Rennie, Stuart, Nieuwkerk, Pythia T., de Bree, Godelieve J., van Paassen, Pien, Dijkstra, Maartje, Peay, Holly L., Rokx, Casper, Verbon, Annelies, Reiss, Peter, Prins, Jan M., Henderson, Gail E., Rennie, Stuart, Nieuwkerk, Pythia T., and de Bree, Godelieve J.

Abstract

Background: People who initiate antiretroviral therapy (ART) during acute HIV infection are potential candidates for HIV cure-related clinical trials, as early ART reduces the size of the HIV reservoir. These trials, which may include ART interruption (ATI), might involve potential risks. We explored knowledge and perception of HIV cure and willingness to participate in cure-related trials among participants of the Netherlands Cohort Study on Acute HIV infection (NOVA study), who started antiretroviral therapy immediately after diagnosis of acute HIV infection. Methods: We conducted 20 in-depth qualitative interviews with NOVA study participants between October–December 2018. Data were analyzed thematically, using inductive and iterative coding techniques. Findings: Most participants had limited knowledge of HIV cure and understood HIV cure as complete eradication of HIV from their bodies. HIV cure was considered important to most participants, mostly due to the stigma surrounding HIV. More than half would consider undergoing brief ATI during trial participation, but only one person considered extended ATI. Viral rebound and increased infectiousness during ATI were perceived as large concerns. Participants remained hopeful of being cured during trial participation, even though they were informed that no personal medical benefit was to be expected. Interpretation: Our results highlight the need for thorough informed consent procedures with assessment of comprehension and exploration of personal motives prior to enrollment in cure-related trials. Researchers might need to moderate their expectations about how many participants will enroll in a trial with extended ATI.

Published
2022

46. Attitudes Toward Striving for Quality and Length of Life Among Patients With Advanced Cancer and a Poor Prognosis

Author

MS Medische Oncologie, Cancer, van der Velden, Naomi C A, van Laarhoven, Hanneke W M, Nieuwkerk, Pythia T, Kuijper, Steven C, Sommeijer, Dirkje W, Ottevanger, Petronella B, Fiebrich, Helle-Brit, Dohmen, Serge E, Creemers, Geert-Jan, de Vos, Filip Y F L, Smets, Ellen M A, Henselmans, Inge, MS Medische Oncologie, Cancer, van der Velden, Naomi C A, van Laarhoven, Hanneke W M, Nieuwkerk, Pythia T, Kuijper, Steven C, Sommeijer, Dirkje W, Ottevanger, Petronella B, Fiebrich, Helle-Brit, Dohmen, Serge E, Creemers, Geert-Jan, de Vos, Filip Y F L, Smets, Ellen M A, and Henselmans, Inge

Published
2022

47. Barrett Esophagus: Quality of life and factors associated with illness perception

Author

MS MDL 1, Cancer, van der Ende-van Loon, Mirjam C.M., Nieuwkerk, Pythia T., van Stiphout, Stephan H.C., Scheffer, Robert C.H., de Ridder, Rogier J.J., Pouw, Roos E., Alkhalaf, Alaa, Weusten, Bas L.A.M., Curvers, Wouter L., Schoon, Erik J., MS MDL 1, Cancer, van der Ende-van Loon, Mirjam C.M., Nieuwkerk, Pythia T., van Stiphout, Stephan H.C., Scheffer, Robert C.H., de Ridder, Rogier J.J., Pouw, Roos E., Alkhalaf, Alaa, Weusten, Bas L.A.M., Curvers, Wouter L., and Schoon, Erik J.

Published
2022

50. Predicting viral load suppression by self- reported adherence, pharmacy refill counts and Real Time Medication Monitoring among people living with HIV in Tanzania

Author

Ngowi, Kennedy M., primary, Minja, Linda, additional, Boer, I. Marion Sumari-de, additional, Aarnoutse, Rob E., additional, Masika, Lyidia, additional, Sprangers, Mirjam A.G., additional, Pima, Francis M., additional, Mmbaga, Blandina T., additional, Reiss, Peter, additional, and Nieuwkerk, Pythia T., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results